EP0663830A1 - Methode de traitement de maladie pulmonaire a l'aide d'uridine-triphosphates - Google Patents

Methode de traitement de maladie pulmonaire a l'aide d'uridine-triphosphates

Info

Publication number
EP0663830A1
EP0663830A1 EP92922217A EP92922217A EP0663830A1 EP 0663830 A1 EP0663830 A1 EP 0663830A1 EP 92922217 A EP92922217 A EP 92922217A EP 92922217 A EP92922217 A EP 92922217A EP 0663830 A1 EP0663830 A1 EP 0663830A1
Authority
EP
European Patent Office
Prior art keywords
atp
utp
amiloride
range
uridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP92922217A
Other languages
German (de)
English (en)
Other versions
EP0663830B1 (fr
EP0663830A4 (fr
Inventor
Richard C. Boucher, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
University of North Carolina System
Original Assignee
University of North Carolina at Chapel Hill
University of North Carolina System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, University of North Carolina System filed Critical University of North Carolina at Chapel Hill
Publication of EP0663830A1 publication Critical patent/EP0663830A1/fr
Publication of EP0663830A4 publication Critical patent/EP0663830A4/fr
Application granted granted Critical
Publication of EP0663830B1 publication Critical patent/EP0663830B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics

Definitions

  • This invention relates to a method of removing retained mucus secretions from the lungs of a patient by administering certain uridine triphosphates to the lungs of the patient.
  • Extracellular adenosine triphosphate has been shown to regulate a variety of biological processes including non—vascular smooth muscle contraction (M. Maguire and D. Satchell, J. Pharmacol . Exp. Ther. 211, 626-631 (1979) ; C. Brown and G. Burnstock, Eur. J. Pharmacol . 69, 81-86 (1981)) and vascular tone (G. Burnstock and C. Kennedy, Circ. Res . 58, 319-330 (198 ⁇ ) ; D. Haeussinger et al., Eur. J. Biochem. 167, 65-71 (1987)), platelet aggregation (G. Born and M. Kratzer, J. Physiol . (Lond.
  • Purinergic receptor regulation of ion transport might have potential therapeutic benefit in lung diseases characterized by abnormalities in epithelial ion transport, e.g., cystic fibrosis.
  • cystic fibrosis the airway epithelial dysfunction is expressed in part by defective regulation of Cl " ion transport by secretagogues that regulate the apical cell membrane Cl " channel by cAMP-dependent or protein kinase C dependent mechanisms (R. Boucher et al., J. Clin. Invest. 78, 1245-1252 (1986); R. Boucher et al., J. Clin. Invest. 84, 1424-1431 (1989); J. Riordan et al., Science 245, 1066-1073 (1989); J.
  • a method of hydrating mucous secretions in the lungs of a subject in need of such treatment comprises administering to the lungs of the subject a compound of Formula I below, or a pharmaceutically acceptable salt thereof (hereinafter referred to as the "active compound") , in an amount effective to hydrate lung mucous secretions:
  • X X 2 , and X 3 are each independently either 0 " or S " .
  • X 2 and X 3 are 0 " .
  • R is O, imido, methylene, or dihalomethylene (e.g., dichloromethylene, difluoromethylene) .
  • R is oxygen.
  • R 2 is H or Br.
  • R 2 is H.
  • Particularly preferred compounds of Formula (I) above are uridine 5'-triphosphate (UTP) and uridine 5'-0-(3- thiotriphosphate) (UTP ⁇ S) .
  • the method of the present invention may further comprise the step of concurrently administering amiloride to the subject in an amount effective to inhibit the reabsorption of water from lung mucous secretions.
  • a second aspect of the present invention is a pharmaceutical formulation containing the active compounds disclosed herein, in an amount effective to hydrate lung mucous secretions, in a pharmaceutically acceptable carrier.
  • the pharmaceutical formulation may further contain amiloride in an amount effective to inhibit the reabsorption of water from lung mucous secretions.
  • a third aspect of the present invention is the use of the active compounds disclosed herein for the manufacture of a medicament for the therapeutic hydration of mucous secretions in the lungs of a patient in need of such treatment.
  • Figure 1 shows the log concentration-effect curves (percent change in I sc from basal levels) of nucleotides applied to the basolateral surface of normal human nasal epithelium, s.e. of each data point is ⁇ 15 % of the normalized maximum response.
  • Figure 2 shows the log concentration-effect curves (percent change in I sc from basal levels) of nucleotides applied to the apical surface of human nasal epithelium pretreated with amiloride (10" 4 M) . s.e. of each data point is ⁇ 13 % of the normalized maximum resonse.
  • Figure 3 shows the log concentration-effect relationships of purinergic and pyrimidinergic compounds on [Ca 2+ ] j (mean change in [Ca 2+ ],. over basal levels).
  • A comparison of agonists which bind P 2 ⁇ , P 2y or UTP sensitive receptors;
  • B Comparison of other purine agonists with response stimulated by ATP;
  • C Comparison of UTP with other pyrimidine agonists, s.e. of each data point is ⁇ 12 % of the normalized maximum response.
  • Figure 4 shows the representative bioelectric tracings of effect on I sc of extracellular ATP or UTP applied to the apical surface of amiloride-pretreated CF human nasal epithelium.
  • A Cl " secretion in response to ATP;
  • B I sc response to ATP of opposite polarity;
  • C Cl " secretory response to UTP.
  • Figure 5 shows the log concentration-effect curves for changes in I sc from basal levels when ATP or UTP are applied to the apical surface of amiloride-pretreated CF tissues, s.e. of each data point is ⁇ 13 % of the normalized maximum response.
  • Figure 6 shows the log concentration-effect relationships of the effect of ATP and UTP on [Ca 2 *], (change from basal levels) in single CF nasal epithelial cells. s.e. of each data point is ⁇ 8 % of the normalized maximum response.
  • the method of the present invention may be used to hydrate mucous secretions in the lungs of a subject in need of such treatment for any reason, including (but not limited to) retained secretions arising from airway diseases such as cystic fibrosis, chronic bronchitis, asthma, and bronchiectasis. Hydration of the mucous secretions causes allows them to be more easily transported from the lungs via mucociliary action, and hence facilitates the removal of retained mucous secretions.
  • the present invention is concerned primarily with the treatment of human subjects, but may also be employed for the treatment of other mammalian subjects, such as dogs and cats, for veterinary purposes.
  • uridine 5•-triphosphate UDP
  • uridine 5'-0-(3-thiotriphosphate) UTP ⁇ S
  • 5-bromo-uridine 5'-triphosphate 5-BrUTP
  • These compounds are known or may be made in accordance with known procedures, or variations thereof which will be apparent to those skilled in the art. See generally N. Cusack and S. Hourani, Annals N. Y. Acad. Sci . 603, 172- 181 (G. Dubyak and J. Fedan Eds. 1990) (titled "Biological Actions of Extracellular ATP”).
  • UTP may be made in the manner described in Kenner et al., J. Chem. Soc. 1954, 2288; or Hall and Khorana, J. Chem. Soc. 76, 5056 (1954) . See Merck Index, Monograph No. 9795 (11th Ed. 1989) .
  • UTP ⁇ S may be made in the manner described in G. Goody and F. Eckstein, J. Am. Chem. Soc. 93, 6252 (1971) .
  • Formula I herein illustrates uridine triphosphate active compounds in the naturally occuring D configuration, but the present invention also encompasses compounds in the L configuration, and mixtures of compounds in the D and L configurations, unless specified otherwise.
  • the naturally occuring D configuration is preferred.
  • the active compounds disclosed herein may be administered to the lungs of a patient by any suitable means, but are preferably administered by administering an aerosol suspension of respirable particles comprised of the active compound, which the subject inhales.
  • the respirable particles may be liquid or solid.
  • the particles may optionally contain other therapeutic ingredients such as amiloride, with amiloride included in an amount effective to inhibit the reabsorption of water from airway mucous secretions, as described in U.S. Patent No.
  • amiloride includes the pharmaceutically acceptable salts thereof, such as (but not limited to) amiloride hydrochloride.
  • the quantity of amiloride included may be an amount sufficient to achieve dissolved concentrations of amiloride on the airway surfaces of the subject of from about 10 "7 to about 10 "3 Moles/liter, and more preferably from about 10 "6 to about 10 "4 Moles/liter.
  • the active compounds disclosed herein can be prepared in the form of their pharmaceutically acceptable salts.
  • Pharmaceutically acceptable salts are salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects.
  • salts examples include (a) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; and salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p- toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (b) salts formed from elemental anions such as chlorine, bromine, and iodine.
  • inorganic acids for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, ni
  • Particles comprised of active compound for practicing the present invention should include particles of respirable size: that is, particles of a size sufficiently small to pass through the mouth and larynx upon inhalation and into the bronchi and alveoli of the lungs. In general, particles ranging from about 1 to 10 microns in size (more particularly, less than about 5 microns in size) are respirable. Particles of non- respirable size which are included in the aerosol tend to deposit in the throat and be swallowed, and the quantity of non-respirable particles in the aerosol is preferably minimized.
  • Liquid pharmaceutical compositions of active compound for producing an aerosol may be prepared by combining the active compound with a suitable vehicle, such as sterile pyrogen free water.
  • a suitable vehicle such as sterile pyrogen free water.
  • Other therapeutic compounds such as amiloride may optionally be included.
  • Solid particulate compositions containing respirable dry particles of micronized active compound may be prepared by grinding dry active compound with a mortar and pestle, and then passing the micronized composition through a 400 mesh screen to break up or separate out large agglomerates.
  • a solid particulate composition comprised of the active compound may optionally contain a dispersant which serves to facilitate the formation of an aerosol.
  • a suitable dispersant is lactose, which may be blended with the active compound in any suitable ratio (e.g., a 1 to 1 ratio by weight) . Again, other therapeutic compounds such as amiloride may also be included.
  • the dosage of active compound will vary depending on the condition being treated and the state of the subject, but generally may be an amount sufficient to achieve dissolved concentrations of active compound on the airway surfaces of the subject of from about 10 "7 to about 10 "3 Moles/liter, and more preferably from about 10" 6 to about 3 x 10 "4 Moles/liter.
  • the daily dose may be divided among one or several unit dose administrations. Aerosols of liquid particles comprising the active compound may be produced by any suitable means, such as with a pressure-driven aerosol nebulizer or an ultrasonic nebulizer. See U.S. Patent No. 4,501,729 (applicant specifically intends that the disclosure of this and all other patent references cited herein be incorporated herein by reference) .
  • Aerosols of solid particles comprising the active compound may likewise be produced with any solid particulate medicament aerosol generator.
  • Aerosol generators for administering solid particulate medicaments to a subject produce particles which are respirable, as explained above, and generate a volume of aerosol containing a predetermined metered dose of a medicament at a rate suitable for human administration.
  • One illustrative type of solid particulate aerosol generator comprises a chamber having a rotor mounted therein, which rotor carries a gelatin capsule containing a metered dose of dry particle medicament. In use the capsule is pierced, a patient inhales through the chamber, and the rotor is caused to spin at a speed sufficient to dispense the medicament to thereby form an aerosol of dry particles.
  • a second type of illustrative aerosol generator comprises a pressurized canister containing dry particle medicament in a propellant.
  • the propellant is discharged through a metering valve configured to dispense a metered dose of the dry particle medicament into the atmosphere.
  • the propellant evaporates, leaving an aerosol of dry particle medicament.
  • the aerosol may be produced by the aerosol generator at a rate of from about 10 to 150 liters per minute, more preferably from about 30 to 150 liters per minute, and most preferably about 60 liters per minute. Aerosols containing greater amounts of medicament may be administered more rapidly.
  • the present invention is explained in greater detail in the Examples which follow. These examples are intended as illustrative of the invention, and are not to be taken as limiting thereof.
  • ATP UTP, ATP ⁇ S, CTP, GTP, ITP, adenylyl-imidodiphosphate (AMPPNP) , ⁇ , ⁇ —methylene ATP (3, ⁇ -MeATP) , ADP3S, ADP, AMP, UDP, 5-BrUTP, UMP, ATP ⁇ S and dipyridamole were obtained from Boehringer Mannheim Biochemicals (Indianapolis, IN) . ct , ⁇ —methylene ATP ( ⁇ ,9-Me ATP) and amiloride were obtained from Sigma Chemicals (St. Louis, MO). 2-methylthio ATP (2MeSATP) was purchased from Research Biochemicals Inc. (Natick, MA) .
  • Bioelectric properties were measured with confluent onolayers bathed by Ham's F—12 culture solution without hormone supplements (Gibco, Grand Island, NY) .
  • the acetoxymethylester of Fura-2 (Fura-2/AM) and the pentapotassium salt Fura—2 were purchased from Molecular Probes (Eugene, OR) .
  • the pentapotassium salt Fura—2 was -lo ⁇ used at 15 ⁇ M in solution with 150 mM KC1, 20 mM NaCl, 10 mM 4-(2-hydroxyethyl)-l-piperazine- ethanesulfonic acid (HEPES) , and either 5 mM CaCl 2 or 2 mM EGTA.
  • HEPES 4-(2-hydroxyethyl)-l-piperazine- ethanesulfonic acid
  • CaCl 2 5 mM CaCl 2
  • 2 mM EGTA For intracellular calcium studies NaCl Ringer solution at 25°C was employed, containing the following (in millimolar) : 150 NaCl, 5 KC1, 5 D-glucose, 10 HEPES, 2 CaCl 2 , 2 MgCl 2 , adjusted to pH 7.4.
  • 2 mM EGTA replaced the CaCl 2 .
  • CMS permeable collagen matrix supports
  • Confluent monolayers of primary human nasal epithelium were mounted in modified Ussing chambers in accordance with known procedures. See, e. g. , R. Boucher et al., J. Physiol . (Lond. ) 405, 77-103 (1988); M.
  • the fluorescent signal was quenched by a NaCl ringer solution containing 1.5 X 10 -4 M digitonin and 10 ⁇ 3 M MnCl 2 .
  • the remaining signal at each excitation wavelength equivalent to the background fluorescence in non—loaded cells, was subtracted from data from Fura—2/AM loaded cells before the ratio (340nm/380nm) was taken.
  • the 340nm/380nm ratio was converted to an actual [Ca 2 *],. measurement by using the external calibration standards and the formula derived by G. Grynkiewicz et al., J. Biol . Chem.
  • [Ca 2+ ] j K [ (R ⁇ —R 0 )/(R S —R ⁇ ) ] , with R 0 and R s representing the ratios at 0 Ca 2 * and saturating Ca 2+ , respectively.
  • R ⁇ represents the experimental ratio.
  • K is K ⁇ F ⁇ F,.)
  • K d 1.57 X 10 ⁇ 7 M at 25 ⁇ C as the effective dissociation constant for Fura—2
  • F 0 and F s represent the fluorescence intensities at 380 nm with zero and saturating Ca 2+ , respectively.
  • a concentration-effect relationship was found when ATP was applied to normal human nasal epithelium under basal conditions (data not shown) . Comparisons were made between responses of tissues from different donors based on the peak change in l sc following ATP application. The curve describes the mean peak change in I in response to log increasing concentrations of ATP applied to the apical or basolateral surface. The effectiveness of the nucleotide is approximately equal when applied to the apical or basolateral surface between 10 ⁇ 7 and 10 -4 M. A large increase in I sc is seen with 10 ⁇ 3 M ATP applied to the basolateral membrane that is not seen with apical application.
  • Concentration-effect relationships were also found for ATP applied to the apical or basolateral membrane of amiloride-pretreated tissues (data not shown). Again, the nucleotide's effect on ion transport was examined as the mean peak change in I sc after ATP application. The change in ion transport induced by ATP in amiloride-pretreated tissues is routinely smaller than that observed in tissues in the basal state. The potency and effectiveness of ATP in amiloride-treated tissues are similar whether applied to the apical or basolateral membrane and the log concentration-effect curves are sigmoidal in character, with EC 50 values of approximately 1-2 X 10 "5 M.
  • the purinergic receptor subtype(s) linked to regulation of ion transport of human nasal epithelium were characterized by obtaining concentration-effect relationships for a variety of purine and pyrimidine agonists in preparations derived from normal and CF patients.
  • receptor subtype(s) on the basolateral surface by measuring nucleotide effect on basal Na + transport rates. Because therapies designed to induce Cl " secretion might best be delivered by the aerosol route, receptor subtype characterization on the apical barrier was performed in the presence of amiloride.
  • the effect of extracellular nucleotides on ion transport is reported as the percent change in I sc from control values when applied to the basolateral or apical surface of the culture. Basal pre—agonist currents were similar for tissues in each concentration group.
  • Figure 1 illustrates the concentration-effect relationships of agonists applied to the basolateral surface of airway epithelium.
  • Figure 3C shows a comparison of UTP (O) with other pyrimidine agonists, mean basal [Ca 2 *],.
  • ATP, UTP and ATP ⁇ S were the most effective agonists.
  • Classical P 2 ⁇ ( ⁇ /3MeATP and ⁇ MeATP) and P 2y (2MeSATP and ADP/3S) receptor agonists had little effect (Figure 3A) as did other analogs of ATP and ADP ( Figure 3B) .
  • 5BrUTP was essentially as effective as UTP for stimulation of Ca 2 * mobilization ( Figure 3C) .
  • Figure 4 provides representative bioelectric tracings of effect on I sc of extracellular ATP (10 -4 M) or UTP (10"* M) applied to the apical surface of amiloride-pretreated (10 "4 M) CF human nasal epithelium.
  • Figure 5 shows log concentration-effect curves for changes in I from basal levels when ATP or UTP are applied to the apical surface of amiloride-pretreated (10" 4 M) CF tissues.
  • s.e. of each data point is ⁇ 13 % of the normalized maximum response.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Méthode destinée à hydrater les sécrétions muqueuses des poumons d'un patient nécessitant un tel traitement qui consiste à administrer aux poumons dudit patient une uridine-triphosphate telle que de l'uridine-5'-triphosphate (UTP) ou de l'uridine-5'O-(3-thiotriphosphate) (UTPηS) dans une quantité efficace pour hydrater les sécrétions muqueuses pulmonaires. La présente méthode est utile pour traiter des patients atteints de maladie kystique du poumon. Des compositions pharmaceutiques et des procédés de préparation desdites compositions sont également décrits.
EP92922217A 1991-06-19 1992-10-09 Methode de traitement de maladie pulmonaire a l'aide d'uridine-triphosphates Expired - Lifetime EP0663830B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/717,747 US5292498A (en) 1991-06-19 1991-06-19 Method of treating lung disease with uridine triphosphates
PCT/US1992/008620 WO1994008593A1 (fr) 1991-06-19 1992-10-09 Methode de traitement de maladie pulmonaire a l'aide d'uridine-triphosphates

Publications (3)

Publication Number Publication Date
EP0663830A1 true EP0663830A1 (fr) 1995-07-26
EP0663830A4 EP0663830A4 (fr) 1996-01-24
EP0663830B1 EP0663830B1 (fr) 2002-04-17

Family

ID=26785072

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92922217A Expired - Lifetime EP0663830B1 (fr) 1991-06-19 1992-10-09 Methode de traitement de maladie pulmonaire a l'aide d'uridine-triphosphates

Country Status (8)

Country Link
US (1) US5292498A (fr)
EP (1) EP0663830B1 (fr)
JP (1) JPH08502078A (fr)
AU (1) AU688258B2 (fr)
DE (1) DE69232565T2 (fr)
ES (1) ES2173869T3 (fr)
NO (1) NO309176B1 (fr)
WO (1) WO1994008593A1 (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551445A4 (en) * 1990-10-05 1994-05-11 Univ North Carolina Method of administering amiloride
EP0517573A1 (fr) * 1991-06-05 1992-12-09 Synthelabo Compositions pharmaceutiques pour le traitement des affections des voies respiratoires
US5512269A (en) * 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
US5514665A (en) * 1993-12-30 1996-05-07 University Of British Columbia Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
US6204382B1 (en) 1994-08-05 2001-03-20 Cytec Technology Corp. Carboxylated amino-1,3,5-triazines, derivatives thereof and processes for preparing the same
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US20020115632A1 (en) * 1995-04-13 2002-08-22 Milkhaus Laboratory, Inc. Treatment of symptoms of asthma and allergies
US20030032614A1 (en) * 1995-04-13 2003-02-13 Mcmichael John Method of treating respiratory distress using synthetic polynucleic acids
US5948768A (en) * 1995-04-13 1999-09-07 Milkhaus Laboratory Treatment of otitis media by sublingual administration of DNA
JP2961709B2 (ja) * 1995-04-13 1999-10-12 ミルカウス ラボラトリー， インコーポレイテッド 呼吸器系疾患の治療方法および治療用薬剤組成物
US6096721A (en) * 1995-04-13 2000-08-01 Milkhaus Laboratory, Inc. Method for treating mucositis by sublingual administration of DNA
US5908611A (en) * 1995-05-05 1999-06-01 The Scripps Research Institute Treatment of viscous mucous-associated diseases
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US6423694B1 (en) * 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
US6420347B1 (en) * 1997-03-27 2002-07-16 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
US6673779B2 (en) * 1996-03-27 2004-01-06 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with dinucleoside polyphosphate compounds or UTP analogues
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
DE69736468T2 (de) * 1996-03-27 2007-03-29 Inspire Pharmaceuticals, Inc. Verfahren zur behandlung der ziliardyskinesie mit uridintriphosphaten und verwandten verbindungen
US5968913A (en) * 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US5962432A (en) * 1996-07-03 1999-10-05 Inspire Pharmaceuticals, Inc. Sterilized, isotonic and pH-adjusted pharmaceutical formulation of uridine triphosphate
US5789391A (en) * 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) * 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6159952A (en) * 1996-11-07 2000-12-12 Inspire Pharmaceuticals, Inc. Method of treating bronchitis with uridine triphosphate and related compounds
US6696425B2 (en) * 1997-02-06 2004-02-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
CN1262556C (zh) * 1997-02-06 2006-07-05 印斯拜尔药品股份有限公司 特定的二核苷酸和它们作为粘膜纤毛清除和纤毛颤动频率调节剂的应用
US6921755B2 (en) * 1998-02-06 2005-07-26 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
US6998121B2 (en) * 2003-01-23 2006-02-14 Milkhaus Laboratory, Inc. Method of treatment of connective tissue disorders by administration of streptolysin O
DK1012154T3 (da) 1997-07-25 2004-07-26 Inspire Pharmaceuticals Inc Salte af di(uridin-5'-tetraphosphat), fremgangsmåde til fremstilling og anvendelser deraf
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
ID29198A (id) * 1997-08-29 2001-08-09 Univ North Carolina Pemakaian uridin 5'-difosfat dan persamaannya untuk mengobati penyakit paru-paru
WO1999061012A2 (fr) 1998-05-22 1999-12-02 Inspire Pharmaceuticals, Inc. Dinucleotides therapeutiques et leurs derives
US6294188B1 (en) 1998-07-09 2001-09-25 Aviana Biopharm Inc. Methods involving changing the constitutive and stimulated secretions of the local reproductive system of women
KR20010099865A (ko) 1998-12-22 2001-11-09 프란시스 제이 메이어 기도 질병 치료용 화합물과 그의 치료 방법 및 기도약물의 전달 방법
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US8501911B2 (en) * 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
AU782966B2 (en) * 1999-06-08 2005-09-15 University Of Iowa Research Foundation, The Compounds and methods to enhance RAAV transduction
KR20020038694A (ko) 1999-07-19 2002-05-23 프란시스 제이 메이어 소듐 채널 차단제의 콘쥬게이트 및 그 이용방법
US7241447B1 (en) * 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
MXPA02011710A (es) * 2000-05-30 2004-07-30 Santen Pharmaceutical Co Ltd Promotores de la extension de la ectocornea.
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
US7115585B2 (en) * 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6555675B2 (en) * 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
WO2002062816A1 (fr) * 2001-02-07 2002-08-15 Celltech R & D Limited Nucleotides et dinucleotides non naturels
WO2003000056A1 (fr) 2001-06-25 2003-01-03 Inspire Pharmaceuticals, Inc. Lubrification d'articulation a l'aide d'agonistes purinergiques de type p2y
ATE519493T1 (de) * 2001-06-26 2011-08-15 Univ North Carolina State Blockierendes peptid für die sekretion von entzündungszellen
US20050009777A1 (en) * 2001-07-25 2005-01-13 Mack Stephen Robert Non-natural carbon-linked nucleotides and dinucleotides
CA2465894A1 (fr) * 2001-11-06 2003-05-15 Inspire Pharmaceuticals, Inc. Methode de traitement et de prevention de maladies inflammatoires
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7435724B2 (en) * 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
US20100144602A1 (en) * 2003-01-23 2010-06-10 Milkhaus Laboratory, Inc. Methods of Inhibiting Metastatic Cancer by Administration of Streptolysin O
US7629312B2 (en) 2003-01-23 2009-12-08 Milkhaus Laboratory, Inc. Method of treatment of tendonitis by administration of streptolysin O
US20050095225A1 (en) * 2003-03-31 2005-05-05 Engelhardt John F. Compounds and methods for pharmico-gene therapy of epithelial sodium channel associated disorders
EP2465852A1 (fr) 2003-08-18 2012-06-20 Parion Sciences, Inc. Inhibiteurs de canal sodique à pyrazinoylguanidine coiffée
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
RU2423379C2 (ru) 2005-01-20 2011-07-10 Байомарк Фармасьютикалз, Лтд. Ингибиторы гиперсекреции муцина и способы их применения
US7851456B2 (en) * 2005-06-29 2010-12-14 Inspire Pharmaceuticals, Inc. P2Y6 receptor agonists for treating lung diseases
US20070021439A1 (en) * 2005-07-25 2007-01-25 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
EP2036567A3 (fr) 2005-12-06 2009-12-09 P2-Science APS modulation de la voie des recepteurs p2y2
US20080182789A1 (en) * 2007-01-30 2008-07-31 Milkhaus Laboratory, Inc. Method of treating pulmonary fibrosis
AU2007243184A1 (en) * 2006-04-28 2007-11-08 University Of Iowa Research Foundation Methods and compounds to modulate parvovirus transduction of mammalian cells or to alter virus infection, method to identify a viral receptor or co-receptor
DK2053915T3 (da) 2006-07-26 2014-06-30 Biomarck Pharmaceuticals Ltd Peptider til reducering af frigørelse af inflammatoriske mediatorer
CA2702094C (fr) 2007-10-10 2018-05-01 Parion Sciences, Inc. Administration d'osmolytes par canule nasale
WO2009139948A1 (fr) 2008-02-26 2009-11-19 Johnson Michael R Bloqueurs poly-aromatiques de canaux sodiques
KR20120050475A (ko) 2009-08-10 2012-05-18 피투-사이언스 에이피에스 협착증 및 제한된 혈류의 기타 상태를 진단하기 위한 ｕｔｐ
AU2011336467A1 (en) 2010-12-01 2013-07-04 Spinal Modulation, Inc. Agent delivery systems for selective neuromodulation
JP6219271B2 (ja) 2011-06-07 2017-10-25 パリオン・サイエンシィズ・インコーポレーテッド 治療の方法
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
WO2013003444A1 (fr) 2011-06-27 2013-01-03 Michael Ross Johnson Dipeptide stable d'un point de vue chimique et métabolique caractérisé par une puissante activité inhibitrice sur les canaux sodiques
EP2809780B1 (fr) 2012-02-01 2018-05-02 Protalix Ltd. Composition liquide inhalable de dnase i
CA2872029A1 (fr) 2012-05-29 2013-12-05 Parion Sciences, Inc. Amino-amides de type dendrimeres possedant une activite de blocage des canaux sodiques pour le traitement de la secheresse oculaire et d'autres maladies des muqueuses
DK2931713T3 (en) 2012-12-17 2017-01-30 Parion Sciences Inc CHLORPYRAZINE CARBOXAMIDE DERIVATIVES USED FOR THE TREATMENT OF DISEASES BENEFITED BY INDEPENDENT MOSPHEREWIN
KR20150095870A (ko) 2012-12-17 2015-08-21 패리온 사이언스 인코퍼레이티드 3,5-디아미노-6-클로로-n-(n-(4-페닐부틸)카르밤이미도일)피라진-2-카르복스아미드 화합물
CA2896686A1 (fr) 2012-12-17 2014-06-26 Parion Sciences, Inc. Composes 3,5-diamino -6-chloro-n-(n- (4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
US11702672B2 (en) 2016-02-08 2023-07-18 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
WO2017155973A1 (fr) 2016-03-07 2017-09-14 University Of Iowa Research Foundation Expression médiée par aav utilisant un promoteur et un activateur synthétiques
WO2021216547A1 (fr) 2020-04-20 2021-10-28 Sorrento Therapeutics, Inc. Administration pulmonaire de polypeptides ace2

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011016A1 (fr) * 1990-12-22 1992-07-09 Fisons Plc Composition pharmaceutique contenant de l'uridine-5'-triphosphate et destinee au traitement de la mucoviscidose

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
JPS60126220A (ja) * 1983-12-09 1985-07-05 Otsuka Pharmaceut Factory Inc 核酸成分組成物
US5100647A (en) * 1990-10-02 1992-03-31 The Trustees Of The University Of Pennsylvania Method and formulations for the therapy of cystic fibrosis, Bartter's syndrome and secretory diarrheas, and for diuretic treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011016A1 (fr) * 1990-12-22 1992-07-09 Fisons Plc Composition pharmaceutique contenant de l'uridine-5'-triphosphate et destinee au traitement de la mucoviscidose

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BR.J.PHARMACOL., vol. 103, no. 3, July 1991 pages 1649-56, 'Regulation of transepithelial ion transport and intracellular calcium by extracellular ATP in human normal and cystic fibrosis airway epithelium' *
FDC REPORTS: THE BLUE SHEET , vol. 34, no. 35, 28 October 1991 pages 4-5, 'Aerosolized amiloride plus atp or utp therapy stimulates lung secretion in cystic fibrosis patients' *
NEW ENGL.J.MED., vol. 325, no. 8, 22 October 1991 pages 533-538, 'Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis' *
See also references of WO9408593A1 *

Also Published As

Publication number Publication date
DE69232565T2 (de) 2002-11-14
ES2173869T3 (es) 2002-11-01
NO951340L (no) 1995-06-02
US5292498A (en) 1994-03-08
AU688258B2 (en) 1998-03-12
JPH08502078A (ja) 1996-03-05
WO1994008593A1 (fr) 1994-04-28
AU2872592A (en) 1994-05-09
NO309176B1 (no) 2000-12-27
NO951340D0 (no) 1995-04-06
EP0663830B1 (fr) 2002-04-17
EP0663830A4 (fr) 1996-01-24
DE69232565D1 (de) 2002-05-23

Similar Documents

Publication Publication Date Title
EP0663830B1 (fr) Methode de traitement de maladie pulmonaire a l'aide d'uridine-triphosphates
US5656256A (en) Methods of treating lung disease by an aerosol containing benzamil or phenamil
DE69725160T2 (de) Verwendung von uridin-triphosphat verwandte verbidungen zur prävention und behandlung von pneumonie in immobilisieren patienten
EP0831777B1 (fr) Dinucleotides utiles dans le traitement de maladies pulmonaires
EP1011688B1 (fr) Utilisation d'uridine 5'-diphosphate et d'analogues de ces derniers pour le traitement de maladies pulmonaires
DE69736468T2 (de) Verfahren zur behandlung der ziliardyskinesie mit uridintriphosphaten und verwandten verbindungen
JP2000514461A (ja) ウリジン・トリホスフェート及び関連化合物による副鼻腔炎の治療方法
DE69724991T2 (de) Behandlung von bronchitis mit diuridintretraphosphat
MX2007015955A (es) Agonistas del receptor p2y6 para el tratamiento de enfermedades pulmonares.
EP1392729A2 (fr) Utilisation d'un peptide qui active la guanylate-cyclase c pour le traitement de maladies des voies respiratoires par les voies aeriennes, medicament, dispositif d'inhalation et methode de diagnostic
US20060116349A1 (en) Methods and compositions for administration of iron for the treatment of restless leg syndrome
DE69821498T2 (de) Verwendung von amifostin
Knowles et al. Pharmacologic modulation of salt and water in the airway epithelium in cystic fibrosis
Rodgers et al. The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis
Richards et al. Additive and non‐additive effects of mixtures of short‐acting intravenous anaesthetic agents and their significance for theories of anaesthesia
AU713021B2 (en) Method of treating lung disease with uridine triphosphates
CN113117090B (zh) 以胞内蛋白纳米颗粒渗透压为靶点治疗人体水肿的药物组合物及应用
Smith et al. Interaction between calcium, neutral endopeptidase and the substance P mediated ciliary response in human respiratory epithelium
CA1334577C (fr) Methode de prevention de la pneumonie a pneumocystic carinii par la pentamidine sous forme d'aerosol
CA3203853A1 (fr) Composition pharmaceutique pour inhalation
DE60207824T2 (de) Cytidin-diphosphocholin gegen diabetische neuropathie
Schreiber et al. Effects of purinergic stimulation, CFTR and osmotic stress on amiloride-sensitive Na+ transport in epithelia and Xenopus oocytes
AU6147794A (en) Use of low density lipoprotein with cytotoxic substances
Vartiainen et al. Development of Inhalable Drug Formulations for Idiopathic Pulmonary Fibrosis
DE19705924A1 (de) Neue Zusammensetzungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950427

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE DK ES FR GB GR IT NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19951205

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): DE DK ES FR GB GR IT NL SE

17Q First examination report despatched

Effective date: 19970822

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/7072 A, 7A 61P 11/10 B, 7A 61P 11/12 B

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/7072 A, 7A 61P 11/10 B, 7A 61P 11/12 B

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): DE DK ES FR GB GR IT NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020417

REF Corresponds to:

Ref document number: 69232565

Country of ref document: DE

Date of ref document: 20020523

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020717

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020717

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2173869

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20030120

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20031003

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20031008

Year of fee payment: 12

Ref country code: GB

Payment date: 20031008

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20031016

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20031128

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041011

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050503

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20041009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050630

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20050501

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051009

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20041011